Compounds > 1-palmitoyl-2-palmitoleoyl-sn-glycero-3-phosphocholine
Page last updated: 2024-12-11
1-palmitoyl-2-palmitoleoyl-sn-glycero-3-phosphocholine
Description
## 1-Palmitoyl-2-palmitoleoyl-sn-glycero-3-phosphocholine (16:0/16:1 PC)
This is a specific type of **phospholipid**, a class of lipids that are major components of cell membranes. Here's a breakdown of the name:
* **1-Palmitoyl:** The first fatty acid chain attached to the glycerol backbone is palmitic acid (16:0), a saturated fatty acid with 16 carbon atoms.
* **2-Palmitoleoyl:** The second fatty acid chain is palmitoleic acid (16:1), a monounsaturated fatty acid with 16 carbon atoms and one double bond.
* **sn-Glycero-3-Phosphocholine:** This indicates the glycerol backbone and the head group, which is phosphocholine.
**Why is it important for research?**
16:0/16:1 PC plays a significant role in various biological processes and has been linked to several diseases:
* **Membrane Fluidity and Structure:** This phospholipid, with its unique combination of a saturated and unsaturated fatty acid, contributes to the fluidity and structural integrity of cell membranes. This impacts membrane function, such as signaling, transport, and enzyme activity.
* **Inflammation:** Studies suggest that 16:0/16:1 PC levels are altered in inflammatory conditions, potentially contributing to their pathogenesis.
* **Cardiovascular Disease:** This phospholipid has been implicated in cardiovascular disease, possibly through its involvement in platelet aggregation and blood clotting.
* **Metabolic Disorders:** 16:0/16:1 PC levels are affected in metabolic disorders like diabetes and obesity, suggesting its role in regulating lipid metabolism and insulin sensitivity.
* **Cancer:** Research is exploring the potential link between 16:0/16:1 PC and cancer, particularly its role in cell growth and proliferation.
**Research Applications:**
16:0/16:1 PC is studied in various research fields:
* **Membrane Biology:** Researchers investigate its role in membrane structure and function, particularly in relation to diseases.
* **Lipidomics:** Analyzing the levels and distribution of 16:0/16:1 PC can provide insights into cell function and disease progression.
* **Drug Development:** Understanding the function of 16:0/16:1 PC can lead to the development of new therapeutic strategies for diseases involving lipid metabolism and membrane dysfunction.
In summary, 16:0/16:1 PC is a vital phospholipid implicated in diverse cellular processes and disease states, making it a crucial molecule for research in understanding membrane biology, inflammation, cardiovascular disease, metabolic disorders, and cancer.
1-palmitoyl-2-palmitoleoyl-sn-glycero-3-phosphocholine: RN given refers to (R-(Z))-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
1-palmitoyl-2-palmitoleoyl-sn-glycero-3-phosphocholine : A phosphatidylcholine 32:1 in which the acyl groups at C-1 and C-2 are hexadecanoyl and (9Z)-hexadec-9-enoyl respectively. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
Synonyms (24)
Synonym |
1-hexadecanoyl-2-(9z-hexadecenoyl)-sn-glycero-3-phosphocholine |
LMGP01010566 , |
pc(16:0/16:1(9z)) |
pc(16:0/16:1) |
ppa-gpc |
[(2r)-3-hexadecanoyloxy-2-[(z)-hexadec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate |
CHEBI:74000 |
(r-(z))-4-hydroxy-n,n,n-trimethyl-10-oxo-7-((1-oxo-9-hexadecenyl)oxy)-3,5,9-trioxa-4-phosphapentacosan-1-aminium, hydroxide, inner salt, 4-oxide |
1-palmitoyl-2-palmitoleoyl-gpc (16:0/16:1) |
(2r)-2-[(9z)-hexadec-9-enoyloxy]-3-(palmitoyloxy)propyl 2-(trimethylammonio)ethyl phosphate |
gpc(16:0/16:1) |
(2r)-3-(hexadecanoyloxy)-2-[(9z)-hexadec-9-enoyloxy]propyl 2-(trimethylazaniumyl)ethyl phosphate |
(2r)-3-(hexadecanoyloxy)-2-[(9z)-hexadec-9-enoyloxy]propyl 2-(trimethylammonio)ethyl phosphate |
1-palmitoyl-2-palmitoleoyl-gpc |
1-hexadecanoyl-2-(9z-hexadecenoyl)-sn-glycero-3-phosphocholine zwitterion |
sn-1-palmitoyl-2-palmitoleoylphosphatidylcholine |
53595-24-7 |
3,5,9-trioxa-4-phosphapentacosan-1-aminium, 4-hydroxy-n,n,n-trimethyl-10-oxo-7-((1-oxo-9-hexadecenyl)oxy)-, hydroxide, inner salt, 4-oxide, (r-(z))- |
(cd3-16.0)(16.1)pc |
1-(16,16,16-trideuteriopalmitoyl)-2-palmitoleoyl-sn-glycero-3-phosphocholine |
1-palmitoyl-2-palmitoleoyl-sn-glycero-3-phosphocholine |
pc 32:1 |
3,5,9-trioxa-4-phosphapentacosan-1-aminium, 4-hydroxy-n,n,n-trimethyl-10-oxo-7-[(1-oxo-9-hexadecenyl)oxy]-, inner salt, 4-oxide, [r-(z)]- |
DTXSID901209735 |
Roles (1)
Role | Description |
mouse metabolite | Any mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus). |
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Drug Classes (2)
Class | Description |
phosphatidylcholine 32:1 | A 1,2-diacyl-sn-glycero-3-phosphocholine in which the acyl groups at C-1 and C-2 contain 32 carbons in total with 1 double bond. |
1-acyl-2-palmitoleoyl-sn-glycero-3-phosphocholine | A 1,2-diacyl-sn-glycero-3-phosphocholine where the acyl group at position 1 is unspecified while the acyl group at position 2 is palmitoleoyl. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (9)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 1 (11.11) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 6 (66.67) | 29.6817 |
2010's | 2 (22.22) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 11.79
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
Metric | This Compound (vs All) |
---|
Research Demand Index | 11.79 (24.57) | Research Supply Index | 2.30 (2.92) | Research Growth Index | 4.09 (4.65) | Search Engine Demand Index | 0.00 (26.88) | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 9 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |